Hemi Dimant
Affiliations: | 2010-2013 | Neurology | Massachusetts General Hospital, Boston, MA |
Google:
"Hemi Dimant"Mean distance: (not calculated yet)
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Hudry E, Martin C, Gandhi S, et al. (2016) Exosome-associated AAV vector as a robust and convenient neuroscience tool. Gene Therapy |
| Dimant H, Zhu L, Kibuuka LN, et al. (2014) Direct visualization of CHIP-mediated degradation of alpha-synuclein in vivo: implications for PD therapeutics. Plos One. 9: e92098 |
| McFarland NR, Dimant H, Kibuuka L, et al. (2014) Chronic treatment with novel small molecule Hsp90 inhibitors rescues striatal dopamine levels but not α-synuclein-induced neuronal cell loss. Plos One. 9: e86048 |
| Dimant H, Kalia SK, Kalia LV, et al. (2013) Direct detection of alpha synuclein oligomers in vivo. Acta Neuropathologica Communications. 1: 6 |
| Dimant H, Ebrahimi-Fakhari D, McLean PJ. (2012) Molecular chaperones and co-chaperones in Parkinson disease. The Neuroscientist : a Review Journal Bringing Neurobiology, Neurology and Psychiatry. 18: 589-601 |
| Dimant H, Solomon B. (2010) Filamentous phages reduce alpha-synuclein oligomerization in the membrane fraction of SH-SY5Y cells. Neuro-Degenerative Diseases. 7: 203-5 |
| Dimant H, Sharon N, Solomon B. (2009) Modulation effect of filamentous phage on alpha-synuclein aggregation. Biochemical and Biophysical Research Communications. 383: 491-6 |
| Dimant H, Sharon N, Solomon B. (2009) P3.004 Modulation of alpha synuclein aggregation by fllamentous phages Parkinsonism & Related Disorders. 15: S148 |